Equities

Bayer AG

0P6S:LSE

Bayer AG

  • Price (EUR)29.26
  • Today's Change0.7675 / 2.69%
  • Shares traded421.33k
  • 1 Year change-45.58%
  • Beta--
Data delayed at least 20 minutes, as of May 16 2024 17:35 BST.
More ▼

Profile data is unavailable for this security.

About the company

Bayer AG is a German-based life science company. The Company's segments are Crop Science, Pharmaceuticals and Consumer Health. The Crop Science segment focuses on seeds, improved plant traits, chemical and biological crop protection products, digital solutions and customer service for sustainable agriculture. The Pharmaceuticals segment focuses on prescription products, especially for cardiology and women's healthcare and specialty therapeutics focused on the areas of cardiology, oncology, hematology and ophthalmology, as well as gene therapy and others. The Consumer Health segment develops, produces and markets nonprescription over-the-counter medicines for self-medication. Its Consumer Health segment portfolio consists of products in dermatology, dietary supplement, analgesic, gastrointestinal, cold, allergy, sinus and flu, foot care and sun protection categories, among others.

  • Revenue in EUR (TTM)47.01bn
  • Net income in EUR-3.12bn
  • Incorporated1952
  • Employees98.19k
  • Location
    Bayer AGKaiser-Wilhelm-Allee 1LEVERKUSEN 51373GermanyDEU
  • Phone+49 214301Fax+49 2 143066328
  • Websitehttps://www.bayer.com/
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.